Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06855771 · ClinicalTrials.gov registry record · Phase 2

A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

A Phase 2 study of Carcinoma, Non-Small Cell Lung, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 2
Development phase
130
Enrollment target
20
Study locations

NCT06855771 is a Phase 2 study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 130 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06855771, a Phase 2 study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 2
Development phase
130 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety and efficacy of BMS-986504 monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion after progression on prior therapies.

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG BMS-986504

Study Locations (20)

New York

  • Memorial Sloan Kettering Cancer Center - New York
  • Local Institution - 0079 - Shirley

Oregon

  • Providence Portland Medical Center - Portland
  • Oregon Health and Science University - Portland

New South Wales

  • GenesisCare - Campbelltown - Campbelltown
  • Chris O'Brien Lifehouse - Camperdown

Alaska

  • Alaska Oncology and Hematology - Anchorage

Idaho

  • Local Institution - 0099 - Boise

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Michigan

  • Karmanos Cancer Institute - Detroit

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2025-09-09
Est. Completion 2031-12-30
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06855771

The ClinicalTrials.gov registry entry for NCT06855771 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (60% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which BMS-986504 is the first listed.

NCT06855771 reports 20 study locations spanning 17 distinct geographic areas - top geographies include New York, Oregon, New South Wales.

Frequently Asked Questions

What is clinical trial NCT06855771 about?

NCT06855771 is a clinical study titled "A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)". The purpose of this study is to evaluate the safety and efficacy of BMS-986504 monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion after progression on prior therapies.

What is the current status of trial NCT06855771?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2025-09-09. Estimated completion is 2031-12-30.

What conditions does trial NCT06855771 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT06855771?

The interventions under investigation include: BMS-986504 (DRUG).

Who is sponsoring clinical trial NCT06855771?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06855771 being conducted?

This trial has 20 study locations across Alaska, Idaho, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Alaska

All trials with a study site in Alaska

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.